Natixis Advisors
IRWD icon

Natixis Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Natixis Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-27,475
Closed -$340K – 1484
2022
Q4 		$340K Buy
+27,475
New +$312K ﹤0.01% 1376
2022
Q3 		– Sell
-26,509
Closed -$306K – 1483
2022
Q2 		$306K Buy
+26,509
New +$312K ﹤0.01% 1370

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Natixis Advisors's IRWD Position: Q1 2023 in Review

Natixis Advisors sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2023, closing a stake of 27,475 shares — an estimated $340K sold.

Natixis Advisors first reported a position in IRWD in Q2 2022 and held it in 2 quarters. The position peaked at $340K in Q4 2022. 254 funds tracked by Wall St. Rank hold IRWD as of Q1 2023.

  • Natixis Advisors reported no remaining Ironwood Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Natixis Advisors sold 27,475 Ironwood Pharmaceuticals shares in Q1 2023, an estimated $340K.
  • Natixis Advisors first reported a position in Ironwood Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Natixis Advisors's Ironwood Pharmaceuticals position peaked at $340K in Q4 2022.
  • 254 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2023.

Based on Natixis Advisors's 13F filing for Q1 2023, filed 11 May 2023.